Search Prime Grants

R01CA264048

Project Grant

Overview

Grant Description
Epigenetic Mechanisms of Carcinogenesis by Parvimonas Micra, an Oral Cavity Commensal Turned Colon Cancer Pathogen - Project Summary

Abstract

Colorectal cancer (CRC) is among the most common malignancies worldwide and has a high mortality rate. In spite of advances in our understanding of the genetics and immunology of CRC, it remains largely resistant to therapy.

Colonization of the large intestine by oral microbes is common among healthy individuals. Many of these commensals have pathophysiological effects in CRC patients. However, their mechanism of action is unclear.

Our recent study identified Parvimonas Micra as the most enriched oral bacteria in CRC patient stool and colon mucosa relative to healthy individuals. Networks of P. Micra and other oral commensals in the stool of CRC patients excluded protective commensals. Changes in DNA methylation of a set of cardinal genes in the colon mucosa and blood of the patients predicted CRC risk.

Transfer of CRC stool to germ-free mice that were treated with AOM resulted in DNA methylation of the host and formation of aberrant crypt foci, over and above that observed with transfer of microbiota from healthy individuals. We provided preliminary data that P. Micra can directly methylate human colon tumor cells when co-cultured together under hypoxic conditions.

On the basis of these findings, we hypothesize that oral commensals exemplified by Parvimonas alter DNA methylation of host DNA to adapt to tumors and promote CRC. We will address this in two specific aims.

Aim 1: We will test the hypothesis that in mouse models of spontaneous CRC, P. Micra alters DNA methylation and expression of host genes that affect CRC tumor growth and tumor-associated immunity. Mice prone to spontaneous CRC will receive healthy human microbiota with or without P. Micra, or L. Acidophilus for comparison. Reduced representation bisulfite sequencing (RRBS), ATACseq, RNAseq, immune assays, and histopathology will determine how changes in DNA methylation impact:
1. The growth and invasion of CRC tumors
2. Tumor-associated inflammation and immune response
3. Microbial community composition of the tumor mucosa and stool.

Aim 2: We will test the hypothesis that P. Micra and bacterial community networks regulate tumor growth and immune response in CRC by altering DNA methylation of host cells. To test this, we will:
1. Identify clusters of fecal and tissue-adherent bacteria in CRC patients and relate these to the DNA hypermethylation of patient colon and blood across different CMS subclasses.
2. Determine how altered DNA methylation of tumor and blood relate to mutation load and immune response.
3. Distinguish pathogenic versus protective patterns of DNA methylation in colon epithelial organoids that result from exposure to P. Micra versus L. Acidophilus.
Funding Goals
TO PROVIDE FUNDAMENTAL INFORMATION ON THE CAUSE AND NATURE OF CANCER IN PEOPLE, WITH THE EXPECTATION THAT THIS WILL RESULT IN BETTER METHODS OF PREVENTION, DETECTION AND DIAGNOSIS, AND TREATMENT OF NEOPLASTIC DISEASES. CANCER BIOLOGY RESEARCH INCLUDES THE FOLLOWING RESEARCH PROGRAMS: CANCER CELL BIOLOGY, CANCER IMMUNOLOGY, HEMATOLOGY AND ETIOLOGY, DNA AND CHROMOSOMAL ABERRATIONS, TUMOR BIOLOGY AND METASTASIS, AND STRUCTURAL BIOLOGY AND MOLECULAR APPLICATIONS.
Grant Program (CFDA)
Place of Performance
Scottsdale, Arizona 852595404 United States
Geographic Scope
Single Zip Code
Analysis Notes
Amendment Since initial award the total obligations have increased 374% from $647,791 to $3,068,738.
Mayo Clinic Arizona was awarded Epigenetic Impact of Parvimonas Micra on Colon Cancer Development Project Grant R01CA264048 worth $3,068,738 from National Cancer Institute in September 2021 with work to be completed primarily in Scottsdale Arizona United States. The grant has a duration of 5 years and was awarded through assistance program 93.396 Cancer Biology Research. The Project Grant was awarded through grant opportunity Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R01 Clinical Trial Not Allowed).

Status
(Ongoing)

Last Modified 9/24/25

Period of Performance
9/13/21
Start Date
8/31/26
End Date
81.0% Complete

Funding Split
$3.1M
Federal Obligation
$0.0
Non-Federal Obligation
$3.1M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to R01CA264048

Transaction History

Modifications to R01CA264048

Additional Detail

Award ID FAIN
R01CA264048
SAI Number
R01CA264048-1875351077
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NC00 NIH National Cancer Institute
Funding Office
75NC00 NIH National Cancer Institute
Awardee UEI
ULMJJBL7ZXX3
Awardee CAGE
1TZ60
Performance District
AZ-01
Senators
Kyrsten Sinema
Mark Kelly

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) Health research and training Grants, subsidies, and contributions (41.0) $1,239,234 100%
Modified: 9/24/25